Print  |  Close

Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer


Active: Yes
Cancer Type: Lung Cancer
Unknown Primary
NCT ID: NCT03847519
Trial Phases: Phase I
Phase II
Protocol IDs: ADXS-503-101 (primary)
NCI-2019-01784
Eligibility: 18 Years and older, Male and Female Study Type: Treatment
Study Sponsor: Advaxis, Inc.
NCI Full Details: http://clinicaltrials.gov/show/NCT03847519

Summary

A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in
Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer

Objectives

To evaluate the safety and tolerability of ADXS-503, administered as monotherapy in Part A
and in combination with pembrolizumab in Part B, and to determine the maximum tolerated dose
(MTD) or maximum administered dose (MAD). As well, to characterize the preliminary anti-tumor
activity of ADXS-503, administered in combination with pembrolizumab in Part C, per RECIST
v1.1.

Treatment Sites in Georgia

Emory University Hospital - Atlanta
1364 Clifton Road NE
Atlanta, GA 30322
www.emoryhealthcare.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.